(SELB) – Selecta Biosciences Stock Is Trading Lower After Gaining Total Rights To MMA Program From AskBio

Based on an internal strategic review and prioritization of its portfolio, Asklepios BioPharmaceutical Inc (AskBio) has decided to give all rights of methylmalonic acidemia (MMA) to Selecta Biosciences Inc (NASDAQ: SELB). MMA program includes gene therapy candidate MMA-101 and ImmTOR for the treatment of methylmalonic acidemia (MMA). Due to a manufacturing issue related to a component sourced from a third party, Selecta now expects that submission of the IND for MMA-101 and ImmTOR will be delayed until the end of this year. The dose-escalation trial of SEL-399, an adeno-associated viral serotype 8 (AAV8) empty vector capsid (EMC-101) containing no DNA combined… Read Full Article Here

(SELB) – Selecta Biosciences Stock Is Trading Lower After Gaining Total Rights To MMA Program From AskBio Topshelf News.

source https://topshelf.news/selb-selecta-biosciences-stock-is-trading-lower-after-gaining-total-rights-to-mma-program-from-askbio/